Clinical Trial Update: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 [Phase 2]

View source ↗

Summary

The Phase 2 study of CA-4948 for treating anemia in patients with very low, low or intermediate risk myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndromes

Drugs mentioned

• CA-4948

Snippet

Sponsor: University of Leipzig | Conditions: Myelodysplastic Syndromes, Anemia | Phase 2 | Status: TERMINATED